

Status: Currently Official on 13-Feb-2025  
 Official Date: Official Prior to 2013  
 Document Type: USP Monographs  
 DocId: GUID-415BC5CF-D6FC-4EC0-848C-8E8D56DA5F1B\_1\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M6338\\_01\\_01](https://doi.org/10.31003/USPNF_M6338_01_01)  
 DOI Ref: 9xw8a

© 2025 USPC  
 Do not distribute

## Atenolol and Chlorthalidone Tablets

» Atenolol and Chlorthalidone Tablets contain not less than 90.0 percent and not more than 110.0 percent of the labeled amounts of atenolol ( $C_{14}H_{22}N_2O_3$ ) and chlorthalidone ( $C_{14}H_{11}ClN_2O_4S$ ).

**Packaging and storage**—Preserve in well-closed containers.

**USP REFERENCE STANDARDS (11)**—

[USP Atenolol RS](#)

[USP Chlorthalidone RS](#)

**Identification**—

**A:** Shake a quantity of powdered Tablets, equivalent to about 50 mg of chlorthalidone, with 5 mL of methanol for 15 minutes, and filter. Apply 10  $\mu$ L of this test solution, 10  $\mu$ L of a Standard solution of [USP Chlorthalidone RS](#) in methanol containing 10 mg per mL, and 10  $\mu$ L of a second Standard solution of [USP Atenolol RS](#) in methanol containing 10J mg per mL, J being the ratio of the labeled amount, in mg, of atenolol to the labeled amount, in mg, of chlorthalidone per Tablet to a thin-layer chromatographic plate (see [Chromatography \(621\)](#)) coated with a 0.25-mm layer of chromatographic silica gel mixture. Allow the spots to dry, and develop the chromatogram in a solvent system consisting of a mixture of *n*-butyl alcohol and 1 N ammonium hydroxide (5:1) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, and air-dry. Locate the spots on the plate by viewing under short-wavelength UV light: the principal spots obtained from the test solution correspond in  $R_f$  value, size, and intensity to those obtained from the respective Standard solutions.

**B:** The retention times of the major peaks in the chromatogram of the *Assay preparation* correspond to those in the chromatogram of the *Standard preparation*, as obtained in the *Assay*.

**DISSOLUTION (711)**—

*Medium:* 0.01 N hydrochloric acid; 900 mL.

*Apparatus 2:* 50 rpm.

*Time:* 45 minutes.

Determine the amounts of atenolol ( $C_{14}H_{22}N_2O_3$ ) and chlorthalidone ( $C_{14}H_{11}ClN_2O_4S$ ) dissolved by employing the following method.

*Mobile phase and Chromatographic system*—Prepare as directed in the *Assay*.

*Diluent*—Prepare a mixture of 1000 mL of acetonitrile and 32 mL of 3.6 N sulfuric acid.

*Standard solvent*—Prepare a mixture of water and *Diluent* (750: 225).

*Standard solution*—Dissolve accurately weighed quantities of [USP Atenolol RS](#) and [USP Chlorthalidone RS](#) in *Standard solvent* to obtain a solution having known concentrations of about 0.00085L mg of [USP Atenolol RS](#) and 0.00085L' mg of [USP Chlorthalidone RS](#) per mL, L and L' being the labeled amounts, in mg, of atenolol and chlorthalidone, respectively, per Tablet.

*Test solution*—Mix 10.0 mL of the filtered solution under test and 3.0 mL of *Diluent*.

*Procedure*—Separately inject equal volumes (about 10  $\mu$ L) of the *Standard solution* and the *Test solution* into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the quantities, in mg, of atenolol ( $C_{14}H_{22}N_2O_3$ ) and chlorthalidone ( $C_{14}H_{11}ClN_2O_4S$ ) dissolved by the same formula:

$$1170C(r_u/r_s)$$

in which C is the concentration, in mg per mL, of the appropriate Reference Standard in the *Standard solution*; and  $r_u$  and  $r_s$  are the responses of the corresponding analyte obtained from the *Test solution* and the *Standard solution*, respectively.

**Tolerances**—Not less than 80% (Q) of the labeled amount of atenolol ( $C_{14}H_{22}N_2O_3$ ) is dissolved in 45 minutes, and not less than 70% (Q) of the labeled amount of chlorthalidone ( $C_{14}H_{11}ClN_2O_4S$ ) is dissolved in 45 minutes.

**UNIFORMITY OF DOSAGE UNITS (905)**: meet the requirements.

*Procedure for content uniformity*—Proceed as directed in the *Assay*, except to prepare the *Assay preparation* as follows. Transfer 1 Tablet to a volumetric flask of such capacity that when filled to volume, a concentration of about 0.25 mg of chlorthalidone per mL is obtained. Add a mixture of water and acetonitrile (1:1) to about half the capacity of the flask, and shake by mechanical means for not less than 15 minutes to disintegrate the Tablet. Dilute with water to volume, and mix. Pass a portion of this solution through a filter having a 0.5- $\mu$ m or finer porosity, and use the filtrate as the *Assay preparation*. Calculate the quantities, in mg, of atenolol ( $C_{14}H_{22}N_2O_3$ ) and chlorthalidone ( $C_{14}H_{11}ClN_2O_4S$ ) in the Tablet taken by the formula:

$$CV(r_U/r_S)$$

in which *V* is the volume, in mL, of the volumetric flask used to prepare the *Assay preparation*; and the other terms are as defined in the *Assay*.

**Assay—**

*Mobile phase*—Prepare a mixture of 740 mL of water, 250 mL of acetonitrile, 8 mL of 3.6 N sulfuric acid, and 930 mg of sodium octyl sulfate. Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*Standard preparation*—Dissolve accurately weighed quantities of [USP Atenolol RS](#) and [USP Chlorthalidone RS](#) in a mixture of water and acetonitrile (3:1) to obtain a solution having known concentrations of about 0.25 mg of [USP Chlorthalidone RS](#) and 0.25*J* mg of [USP Atenolol RS](#) per mL, *J* being the ratio of the labeled amount, in mg, of atenolol to the labeled amount, in mg, of chlorthalidone per Tablet.

*Assay preparation*—Transfer 10 Tablets to a volumetric flask of such capacity that when filled to volume, a concentration of about 0.5 mg of chlorthalidone per mL is obtained. Add a mixture of water and acetonitrile (1:1) to about half the capacity of the flask, and shake by mechanical means for not less than 15 minutes to disintegrate the Tablets. Dilute with a mixture of water and acetonitrile (1:1) to volume, and mix. Pass a portion of this stock solution through a filter having a 0.5-μm or finer porosity. Transfer 25.0 mL of the clear filtrate to a 50-mL volumetric flask, dilute with water to volume, and mix.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 275-nm detector and a 4.6-mm × 25-cm column that contains packing L1. The flow rate is about 1.7 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.8 for atenolol and 1.0 for chlorthalidone; the resolution, *R*, between the atenolol and chlorthalidone peaks is not less than 3.0; and the relative standard deviation for replicate injections is not more than 2.0%.

*Procedure*—Separately inject equal volumes (about 10 μL) of the *Assay preparation* and the *Standard preparation* into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the quantities, in mg, of atenolol (C<sub>14</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>) and chlorthalidone (C<sub>14</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>4</sub>S) in each Tablet taken by the formula:

$$2C(V/10)(r_U/r_S)$$

in which *C* is the concentration, in mg per mL, of the appropriate USP Reference Standard in the *Standard preparation*; *V* is the volume, in mL, of the volumetric flask used to prepare the stock solution for the *Assay preparation*; and *r<sub>U</sub>* and *r<sub>S</sub>* are the responses for the corresponding analyte obtained from the *Assay preparation* and the *Standard preparation*, respectively.

[NOTE—If a trailing peak or shoulder is observed on the chlorthalidone peak with a relative retention time of not more than 1.1 in the chromatograms of both the *Standard preparation* and the *Assay preparation*, sum the areas for the chlorthalidone peak with the trailing peak or shoulder to report the peak responses for chlorthalidone.]

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ATENOLOL AND CHLORTHALIDONE TABLETS	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. 50(2)

**Current DocID:** GUID-415BC5CF-D6FC-4EC0-848C-8E8D56DA5F1B\_1\_en-US

**DOI:** <https://doi.org/10.31003/USPNF.M6338.01.01>

**DOI ref:** [9xw8a](#)